ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 568,66
-0,84%
Dow Jones
40 545,71
0,83%
DAX
18 483,00
-0,63%
Brent Oil
83,145
-1,42%
Bitcoin
63 876,09
-1,50%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
14/02/201821h03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
09/02/201813h00GlobeNewswire Inc.Summit Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
30/01/201818h41Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
25/01/201813h51Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
25/01/201813h00GlobeNewswire Inc.Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical T...NASDAQ:SMMTSummit Therapeutics Inc
09/01/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the Biotech ShowcaseNASDAQ:SMMTSummit Therapeutics Inc
03/01/201819h47Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
23/12/201722h00GlobeNewswire Inc.Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva LtdNASDAQ:SMMTSummit Therapeutics Inc
06/12/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Pro...NASDAQ:SMMTSummit Therapeutics Inc
06/12/201708h00GlobeNewswire Inc.Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy ...NASDAQ:SMMTSummit Therapeutics Inc
04/12/201713h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 201...NASDAQ:SMMTSummit Therapeutics Inc
20/11/201713h00GlobeNewswire Inc.Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialNASDAQ:SMMTSummit Therapeutics Inc
09/11/201713h00GlobeNewswire Inc.Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ...NASDAQ:SMMTSummit Therapeutics Inc
06/11/201715h29GlobeNewswire Inc.Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
25/10/201715h00GlobeNewswire Inc.Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive DirectorsNASDAQ:SMMTSummit Therapeutics Inc
09/10/201713h00GlobeNewswire Inc.Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017...NASDAQ:SMMTSummit Therapeutics Inc
04/10/201713h00GlobeNewswire Inc.Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd ...NASDAQ:SMMTSummit Therapeutics Inc
02/10/201713h00GlobeNewswire Inc.Summit Therapeutics to Host R&D Day 11 October 2017NASDAQ:SMMTSummit Therapeutics Inc
25/09/201713h00GlobeNewswire Inc.Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne...NASDAQ:SMMTSummit Therapeutics Inc
15/09/201719h31GlobeNewswire Inc.Summit Therapeutics Announces Exercise of Underwriters’ Over-Allotment OptionNASDAQ:SMMTSummit Therapeutics Inc
14/09/201723h21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SMMTSummit Therapeutics Inc
14/09/201705h03GlobeNewswire Inc.Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary SharesNASDAQ:SMMTSummit Therapeutics Inc
13/09/201722h35GlobeNewswire Inc.Summit Therapeutics Announces Proposed Public Offering of $15.0 Million of American Depositary SharesNASDAQ:SMMTSummit Therapeutics Inc
11/09/201713h00GlobeNewswire Inc.Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. diff...NASDAQ:SMMTSummit Therapeutics Inc
05/09/201713h00GlobeNewswire Inc.Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Select...NASDAQ:SMMTSummit Therapeutics Inc
31/08/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progre...NASDAQ:SMMTSummit Therapeutics Inc
25/08/201715h30GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017NASDAQ:SMMTSummit Therapeutics Inc
03/08/201713h00GlobeNewswire Inc.Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
22/06/201723h44Dow Jones NewsADRs End Higher; Pharmaceuticals Trade ActivelyNASDAQ:SMMTSummit Therapeutics Inc
22/06/201713h00GlobeNewswire Inc.Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

BIT
F15446
Vontobel Financial Produ...
BIT
UC3U3N
Unicredit Bank
BIT
P1V8J0
NLBNPIT1V8J0 20241220 42...
BIT
F28944
Vontobel Financial Produ...
BIT
ITW
It Way
BIT
J26827
JP Morgan Structured Pro...
BIT
UC5CCU
Unicredit Bank
BIT
P1H4N9
BNP Paribas Issuance
LSE
ARS
Asiamet Resources
LSE
SPLT
Ishs Platinum �
LSE
IEBC
Ishrc Euro
LSE
EXO
Exova
USOTC
VYCO
Vycor Medical (QB)
BOV
VRTA11
Fator Verita Fundo Inves...
NYSE
LB
LandBridge
BIT
P1Y201
NLBNPIT1Y201 20240920 3.2
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés